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Introduction

• Friedreich’s ataxia was first described in 1863 by
German physician Nikolaus Friedreich
• Although a relatively rare disease, it is the most
common form of hereditary ataxia, affecting
approximately 1 in every 50,000 people.
• Friedreich’s ataxia is an autosomal recessive disease
caused by a trinucleotide repeat of GAA in the FXN
gene on Chromosome 9, which codes for the
mitochondrial protein frataxin. This expansion causes
gene silencing and decreased production of frataxin.
• Frataxin incorporates iron cofactors into iron sulfur
clusters which form enzymes involved in electron
transfer and mitochondrial ATP production, which
decreases when frataxin levels are low.
• Cells with low frataxin have lower mitochondrial ATP
production, decreased cellular energy, and
development of toxic free radicals which cause
oxidative damage to DNA in nerve cells, pancreatic
beta cells, and cardiac myocytes.
• This leads to ataxia, diabetes mellitus, and cardiac
complications including hypertrophic cardiomyopathy,
myocardial fibrosis, and heart failure, all which
contribute to cardiac disease being the most common
cause of death in FA.
• Interestingly, about 1 in 90 Americans of European
ancestry is a carrier of an abnormal FXN gene.
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Case Presentation

• A 31-year-old female with FA and cardiomyopathy
presented to the ED with palpitations, dyspnea,
myalgias, diaphoresis, and anxiety after taking a
Canadian weight-loss supplement for 7 days.
• She denied chest pain. Poison control determined the
active ingredient to be 2,4-dinitrophenol.
• Vitals: BP 142/100, HR 120, temp 98.2F.
• Physical exam: tachycardia, skin erythema, and
anxious mood.
• EKG: Sinus tachycardia and lateral T wave inversions.
• CT was negative for pulmonary embolus. Negative
toxicology. Normal lactic acid, CK, metabolic panel.
• Troponin: 2,369 (initial) -> 4,580 (peak).
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Decision Making

• Despite the elevated troponin, Cardiology
advised against typical NSTEMI treatment with IV
Heparin given the low likelihood of plaque rupture
induced ischemic event (Type 1 MI).
• The likely cause of presentation was
demand ischemia (Type 2 MI), this is supported by
her lack of chest pain, mild troponin elevation, and
echocardiogram without ischemic changes.
• She was given supportive care, cardiac
monitoring, Aspirin 324mg, Metoprolol, and
Acetaminophen, and had relief of symptoms after a
few days.
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Discussion

• Given that patients with FA can have an elevated
baseline troponin and already have mitochondrial
dysfunction given low frataxin levels, the 2,4dinitrophenol would impact her fragile cardiomyocytes further as the medication uncouples
mitochondrial phosphorylation leading to increased
metabolic rate, cellular hyperthermia, and can
precipitate cellular death.
• With this mechanism of action, it is not surprising the
patient developed a type II NSTEMI with higherthan-expected troponin.
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